Feb 16, 2022 / 06:30PM GMT
Yigal Dov Nochomovitz - Citigroup Inc., Research Division - Director
Okay. Great. Welcome back, everyone, to the Citi Immuno-Oncology Summit. The next session is with Merus. I'm Yigal Nochomovitz, one of the biotech analysts here at Citi. I think most everyone on the call knows me. If you have questions for management, I'm happy to ask them, just e-mail me at [email protected], and I will relay the questions. So with that, welcome, both Bill Lundberg, CEO of Merus; and Andrew Joe, the CMO. Thank you very much for taking the time.
Bill, maybe as a place to start, for those that are a little bit less familiar with the company, just give a quick overview of the company and the pipeline in brief as well as how your multi-clinic antibody platform is different from what else is out there. Obviously, there's a lot of different flavors of antibody platforms in the industry.
Sven Ante Lundberg - Merus N.V. - CEO, President, Principal Financial Officer & Executive Director
Thanks, Yigal, and thank you for the opportunity to participate in the summit
Merus NV at Citi Immuno-Oncology Summit (Virtual) Transcript
Feb 17, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers